ZITUVIO Drug Patent Profile
Which patents cover Zituvio, and what generic alternatives are available?
Zituvio is a drug marketed by Zydus Lifesciences and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in ZITUVIO is sitagliptin. Two suppliers are listed for this compound. Additional details are available on the sitagliptin profile page.
DrugPatentWatch® Generic Entry Outlook for Zituvio
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 25, 2035. This may change due to patent challenges or generic licensing.
There are twenty-seven tentative approvals for the generic drug (sitagliptin), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
US Patents and Regulatory Information for ZITUVIO
ZITUVIO is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZITUVIO is ⤷ Start Trial.
This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | ZITUVIO | sitagliptin | TABLET;ORAL | 211566-001 | Oct 18, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zydus Lifesciences | ZITUVIO | sitagliptin | TABLET;ORAL | 211566-002 | Oct 18, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zydus Lifesciences | ZITUVIO | sitagliptin | TABLET;ORAL | 211566-003 | Oct 18, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZITUVIO
See the table below for patents covering ZITUVIO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| India | 651MU2014 | ⤷ Start Trial | |
| Philippines | 12016501686 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2015128877 | ⤷ Start Trial | |
| South Africa | 201606075 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZITUVIO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1412357 | C300287 | Netherlands | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER SITAGLIPTINE FOSFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321 |
| 1412357 | 77 5006-2008 | Slovakia | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408 |
| 1412357 | 50/2008 | Austria | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408 |
| 0896538 | 91334 | Luxembourg | ⤷ Start Trial | CERTIFICATE TITLE: SITAGLIPTIN, OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER LE SEL PHOSPHATE (JANUVIA); FIRST REGISTRATION: 20070321 |
| 1412357 | 122007000056 | Germany | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE FUER SITAGLIPTINPHOSPHAT-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321 |
| 1412357 | 132008901682802 | Italy | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTIN/METFORMINA CLORIDRATO(JANUMET, VELMETIA, EFFICIB); AUTHORISATION NUMBER(S) AND DATE(S): JANUMET:EU/1/08/455/001... 014; VELMETIA:EU/1/08/456/001...014;EFFICIB: EU/1/08/457/001....014, 20080716;58450-01;58450-02; 58450-03, 20080408 |
| 1412357 | 122008000046 | Germany | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
